FIXED-DOSE COMBINATION VERSUS SEPARATE ANTITUBERCULOSIS FORMULATIONS IN PULMONARY TUBERCULOSIS PATIENTS: EVALUATION OF EFFECTIVENESS AND SAFETY

  • Rimenda Sitepu Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia,
  • Purwantyastuti Ascobat Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia,
  • Flora Ekasari Department of Pulmonology, Dr. Esnawan Antariksa Hospital, Halim Perdana Kusuma, 13610, Jakarta, Indonesia.
  • Insti Instiaty Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia,

Abstract

Objective: This study aimed to compare the effectiveness and safety of fixed dose combination (FDC) versus separate (separate formulation [SF])
antituberculosis (TB) formulations in patients with bacteriologically confirmed pulmonary TB.
Methods: Data were collected retrospectively from patient records, which included all newly diagnosed bacteriologically confirmed pulmonary
TB patients treated with first category FDC or SF between January 2014 and January 2017 at the Dr. Esnawan Antariksa Hospital. The efficacy of
the formulations was determined according to acid-fast bacilli (AFB) sputum smear conversion at the end of the intensive phase (month 2), after
6 months of therapy, and after the extended treatment phase (month 3). Adverse drug reactions (ADRs) during treatments were recorded as safety
outcomes. Chi-square tests were used to analyze the differences between the groups.
Results: On comparing patients treated with FDC (n=33) and SF (n=30), rates of sputum conversions did not differ significantly after 2 months
(83.3% vs. 78.7%, p=0.693) and the intensive phase was extended by 1 month for patients with conversion failures at this time point. One of seven
patients in the FDC group did not achieve sputum conversion during the extended phase and was recorded as a medication failure. At the end of
continuation phase, all other subjects achieved sputum conversion. The overall frequencies of ADRs were not significantly higher in the FDC group
than that in the SF group (36.4% vs. 23.3%, p=0.260).
Conclusion: No differences in effectiveness and safety profiles were identified between first category FDC and separate anti TB formulations.

Keywords: Tuberculosis, Fixed-dose combination, Separate antituberculosis formulations, Sputum conversion.

References

1. World Health Organization. Global Tuberculosis Report 2014.
Available from: http://www.who.int/tb/publications/global_report/en.
[Last accessed on 2016 Sep 23].
2. World Health Organization. Global Tuberculosis Report 2015.
Available from: http://www.who.int/tb/publications/global_report/en.
[Last accessed on 2016 Sep 23].
3. Department of Health Jakarta. Health Profile of DKI Jakarta Province.
Jakarta: PDKI; 2012.
4. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G,
et al. Efficacy and safety of a 4-drug fixed-dose combination regimen
compared with separate drugs for treatment of pulmonary tuberculosis:
The study C randomized controlled trial. JAMA 2011;305:1415-23.
5. Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T,
et al. Efficacy and safety of ‘fixed dose’ versus ‘loose’ drug regimens
for treatment of pulmonary tuberculosis in two high TB-burden African
countries: A Randomized controlled trial. PLoS One 2016;11:e0157434.
6. Tabrani I. Sputum BTA Conversion at Intensive Phase of Category I
pulmonary TB Between Fixed-Dose Combination and Generic Anti-
Tuberculosis Drug at RSUP H Adam Malik Medan. Thesis. Medan:
Universitas Sumatera Utara; 2007.
7. Immanuel C, Gurumurthy P, Ramachandran G, Venkatesan P,
Chandrasekaran V, Prabhakar R, et al. Bioavailability of rifampicin
following concomitant administration of ethambutol or isoniazid or
pyrazinamide or a combination of the three drugs. Indian J Med Res
2003;118:109-14.
8. Singh S, Bhutani H, Mariappan TT. Quality problems of antituberculosis
fixed dose combination (FDCs): A way forward. Indian J Tuberc
2006;53:201-5.
9. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H,
van der Meer JW, et al. Low plasma concentrations of rifampicin
in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis
2002;6:497‑502.
10. Suryanto AA, Van den Broek J, Hatta M, De Soldenhoff R, Van der
Werf MJ. Is there an increased risk of TB relapse in patient treats with
fixed dose combination drugs in Indonesia? Int J Tuberc Lung Dis
2008;12:174-9.
11. Caesar MD. Comparison Effect of Anti Tuberculosis Fixed Dose
Combination and Separate Drug to Sputum Smear Conversion at
the end of Intensive Phase to Tuberculosis Patient in Surakarta
Community Pulmonary Health Institute. Thesis. Surakarta: Universitas
Muhammadiyah Surakarta; 2014.
12. Bartacek A, Schütt D, Panosch B, Borek M, Rimstar 4-FDC Study
Group. Comparison of a four-drug fixed-dose combination regimen
with a single tablet regimen in smear-positive pulmonary tuberculosis.
Int J Tuberc Lung Dis 2009;13:760-6.
Statistics
145 Views | 138 Downloads
Citations
How to Cite
Sitepu, R., Ascobat, P., Ekasari, F., & Instiaty, I. (2018). FIXED-DOSE COMBINATION VERSUS SEPARATE ANTITUBERCULOSIS FORMULATIONS IN PULMONARY TUBERCULOSIS PATIENTS: EVALUATION OF EFFECTIVENESS AND SAFETY. International Journal of Applied Pharmaceutics, 10(1), 208-210. https://doi.org/10.22159/ijap.2018.v10s1.46
Section
Original Article(s)